616.99
Oncology
Tumour biology, immunotherapy and cancer trials.
Drawer contents
Filled from
PPubMedBbioRxiv
Search threads
cancer immunotherapy response
tumor microenvironment
616.99
Tumour biology, immunotherapy and cancer trials.
Drawer contents
Filled from
Search threads
cancer immunotherapy response
tumor microenvironment
Margarita Gutova, Eric Ma, Heini N. Natri, Sean Sepulveda + 14 more
Pediatric and adult brain tumors, including glioblastoma, astrocytoma, ependymoma, and medulloblastoma, remain associated with poor prognosis despite advances in surgery, radiation, and chemotherapy. Therapeutic resistance, tumor heterogeneity, and treatment-related toxicity highlight the need for clinically relevant…
Sixuan Chen, Liping Tu, Quanhua Chen
The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution. This review synthesizes the theoretical foundations, historical evolution, clinical…
Xingzhi Niu, Deepali Kundnani, Mikaela Dicome, Luis Tafoya + 4 more
Clinical response to immune checkpoint blockade (ICB) remains variable. We performed a reference-wide screen to identify immune-cell populations in the tumor microenvironment (TME) associated with benefit across treatment modalities and tumor types. We analyzed pretreatment bulk tumor RNA-seq to identify RNA-abundance…
Mohammed S. Teiama, Asmaa Gohar, Mahmoud Amr, Mohamed El-Shinawi + 1 more
Cancer remains a major global health burden and the second leading cause of mortality worldwide. Recent advances in cancer immunotherapy have emphasized the critical role of the tumor microenvironment (TME) in determining therapeutic outcomes, leading to the classification of tumors into immunologically “hot” and…
Patricia Lamirande, Mia Brunetti, Terry Easlick, Fatemeh Beigmohammadi + 1 more
Mechanistic mathematical models have been used extensively to provide a deeper understanding of biological mechanisms, including unveiling the regulation of tumour growth and its response to various treatments. However, given the breadth of biological regulatory mechanisms, these models are frequently large and thus…
Lucrezia Paradisi, Lorenza Trabalzini, Federica Finetti
Cytoskeletal reorganization is fundamental to essential cellular processes, including shape maintenance, migration, adhesion cytokinesis, and phagocytosis, and its dysregulation is a hallmark of tumor progression. In cancer cells, altered cytoskeletal dynamics promote invasion and genomic instability resulting from…
Mingzhou Li, Bingyu Xu, Jieqiong Wu, Zhengyu Zhang + 15 more
The spatial architecture of the tumor microenvironment (TME) is pivotal in the progression of colorectal cancer (CRC) liver metastasis. By applying high-plex spatial multi-omic mapping and neighborhood analysis to a discovery cohort of colorectal cancer primary tumor (PT) and paired liver metastases (LM), we identified…
Alia Syazana Mohd Roslei, Hasniza Zaman Huri, Dyah Ayu Oktavianie A. Pratama, Ahmad Khusairi Azemi + 10 more
Brain cancer is one of the most challenging malignancies and a major contributor to worldwide morbidity and mortality. Glioblastoma, the most aggressive adult brain tumor, is associated with poor prognosis despite conventional therapies such as surgery, chemotherapy, and radiotherapy, which often result in severe…
Corey Keith Goldman
Peptide cancer vaccines can elicit antigen-specific immunity, but peripheral immunogenicity often does not translate into durable tumor control. We analyzed transcriptomic profiles across three public human peptide-vaccine cohorts: C1/GSE278476, a MUC1 plus Poly-ICLC PBMC RNA-seq cohort with ordered anti-MUC1 IgG…
Ling Li, Shuai Zhao, Xiaoxiao Wang, Jiahui Du + 3 more
Breast cancer ranks first in global cancer incidence. Due to its high heterogeneity, cancer cells often develop drug resistance during metastasis, leading to therapeutic challenges and poor prognosis. Consequently, breast cancer organoid models have emerged, which can effectively recapitulate the tumor microenvironment…
Mary Oluwabusolami Odubote, Chiemeka Elochi Emeribe
Tumor progression is driven by dynamic interactions between malignant cells and the tumor microenvironment (TME), yet the regulatory mechanisms governing cellular heterogeneity and intercellular communication remain incompletely characterized. Here, we performed integrative single-cell RNA sequencing (scRNA-seq)…
Katsuhiro Yoshimura, Daniela B. Rodriguez-Perera, Rongzhang Dou, Johannes Fahrmann
Title: Graphical Abstract
Nicolas Deredec, Lisa Aziez, Ismael Boussaid, Justine Decroocq + 15 more
The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3^+^) and tumor plasma B cells (BCMA^+^) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3×BCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent…
Yi Liu, Dingling Yin, Lu Wu, Huan Wang + 7 more
Introduction Cervical cancer is a common gynecological malignancy, having high incidence and mortality rates, especially in developing regions. The tumor microenvironment (TME) plays a crucial role in disease progression, and cancer-associated fibroblasts (CAFs) are key components of the TME. However, the roles of CAFs…
Jennifer Q. Pfeil, Shirley Hui, Daniel Stueckmann, Xiaoyu Zhang + 25 more
Renal cell carcinoma (RCC) is amongst the most immune-infiltrated solid tumours, but only a small subset of patients achieves durable response to immune checkpoint blockade therapy. Efforts to characterize the immune microenvironment and molecular regulators responsible for treatment responses have explored numerous…
Mengyan Xie, Chao Wang, Jun Zhang, Xinming Jing + 2 more
Objective Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but reliable peripheral blood biomarkers for monitoring treatment response and predicting prognosis remain limited. This study aimed to analyze the dynamic changes of lymphocyte subsets in patients receiving ICI therapy, evaluate their…
Wen Zhang, Shiliang Ji
Bladder cancer has entered an era in which immune checkpoint blockade (ICB) and antibody-drug conjugate (ADC)-based combinations are reshaping clinical management. However, transcriptomic scores that connect prognosis, tumor microenvironment state, and treatment response are incompletely defined. Open-access TCGA-BLCA…
Jianing Zhang, Zimei Tang, Yiran Wang, Jiaying Wan + 5 more
Metabolic reprogramming constitutes a fundamental hallmark of malignancy, orchestrating a hostile tumor microenvironment (TME) that severely compromises anti-tumor immunity. Despite the transformative success of immune checkpoint blockade and adoptive cell therapies, clinical efficacy is frequently curtailed by the…
Julian Burks, Ying Wu, Krithika Bhuvaneshwar, Neeraja Syed + 13 more
While recent research has increasingly focused on the role of fibroblasts and macrophages in osteosarcoma, the tumor vasculature remains poorly understood, particularly in metastatic disease. To address this gap, we performed single-nuclei multi-ome (RNA+ATAC) sequencing on 24 human metastatic osteosarcoma specimens.…
Tauana Christina Dias, Jéssica Ferreira Vieira, Katiane Tostes, Polyana Barbosa Silva + 6 more
Aim: Breast cancer remains a major cause of cancer-related mortality in women, particularly in advanced stages where therapeutic options are limited. While immune checkpoint inhibitors (ICIs) have improved outcomes in a subset of patients, many do not respond, highlighting the need for alternative immunotherapeutic…
Yuang Song, Ekaterina Aladyeva, Ruan F. Vieira Medrano, Derek J Theisen + 17 more
Personalized neoantigen (neoAg) vaccines have shown clinical promise in solid tumors^1–8^, yet their efficacy and mechanism of action in hematopoietic malignancies remain poorly defined^9–11^. Herein, we establish an immunocompetent syngeneic A20 B-cell lymphoma platform to test the efficacy of neoAg vaccines used…